Mamedov Tarlan, Yuksel Damla, Gurbuzaslan Irem, Ilgin Merve, Gulec Burcu, Mammadova Gulshan, Ozdarendeli Aykut, Pavel Shaikh Terkis Islam, Yetiskin Hazel, Kaplan Busra, Uygut Muhammet Ali, Hasanova Gulnara
Department of Agricultural Biotechnology, Akdeniz University, Antalya, Türkiye.
Institute of Molecular Biology and Biotechnologies, Ministry of Science and Education, Republic of Azerbaijan, Baku, Azerbaijan.
Front Plant Sci. 2023 Aug 2;14:1202570. doi: 10.3389/fpls.2023.1202570. eCollection 2023.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel and highly pathogenic coronavirus that caused an outbreak in Wuhan City, China, in 2019 and then spread rapidly throughout the world. Although several coronavirus disease 2019 (COVID-19) vaccines are currently available for mass immunization, they are less effective against emerging SARS-CoV-2 variants, especially the Omicron (B.1.1.529). Recently, we successfully produced receptor-binding domain (RBD) variants of the spike (S) protein of SARS-CoV-2 and an antigen cocktail in , which are highly produced in plants and elicited high-titer antibodies with potent neutralizing activity against SARS-CoV-2. In this study, based on neutralization ability, we demonstrate that plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variants. These data demonstrate that plant-produced RBD and cocktail-based proteins are the most promising vaccine candidates and may protect against Delta and Omicron-mediated COVID-19. This is the first report describing vaccines against SARS-CoV-2, which demonstrate significant activities against Delta and Omicron variants.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新型高致病性冠状病毒，于2019年在中国武汉市引发疫情，随后迅速蔓延至全球。尽管目前有几种2019冠状病毒病（COVID-19）疫苗可用于大规模免疫接种，但它们对新出现的SARS-CoV-2变体效果较差，尤其是奥密克戎（B.1.1.529）变体。最近，我们成功在植物中生产了SARS-CoV-2刺突（S）蛋白的受体结合域（RBD）变体和一种抗原混合物，它们在植物中大量产生，并引发了对SARS-CoV-2具有强大中和活性的高滴度抗体。在本研究中，基于中和能力，我们证明植物产生的RBD和基于混合物的候选疫苗对SARS-CoV-2高度有效，与其新出现的变体无关。这些数据表明，植物产生的RBD和基于混合物的蛋白质是最有前途的候选疫苗，可能预防由德尔塔和奥密克戎介导的COVID-19。这是第一份描述针对SARS-CoV-2疫苗的报告，该疫苗对德尔塔和奥密克戎变体显示出显著活性。
